000			00995nam a22002417a 4500
020			_a978-967-0747-26-2
082			_a615.32 _bAMI
100			_aAmit Senguta
245			_aBiological Drugs: Challenges to Access
260			_aMalaysia: _bThird World Network, _c2018.
300			_a38p.
650			_aThe Growing Therapeutic and Commercial Importance
650			_aHow Biological Drugs Differ from Small Molecule Drugs
650			_aRecombinant Technologies in the Manufacture of Biological Drugs
650			_aRenewed Interest in Biological Medicines
650			_aWhy are Biologics and Biosimilars So Expensive
650			_aBiosimilas vs Generics of SMDs
650			_aTechnological Barriers to Manufacture of Biosimilars
650			_aBarriers Related to Intellectual Property Rights and Data Exclusivity
650			_aThe Evolving Regulatory Landscape for Approval of Biosimilars
650			_aHow necessary are Present Requirements to Establish Similarity
942			_cCR
999			_c344744 _d344744